TY - JOUR
T1 - Rational design of HIV vaccines and microbicides
T2 - Report of the EUROPRISE network annual conference 2010
AU - Brinckmann, Sarah
AU - da Costa, Kelly
AU - van Gils, Marit J.
AU - Hallengärd, David
AU - Klein, Katja
AU - Madeira, Luisa
AU - Mainetti, Lara
AU - Palma, Paolo
AU - Raue, Katharina
AU - Reinhart, David
AU - Reudelsterz, Marc
AU - Ruffin, Nicolas
AU - Seifried, Janna
AU - Schäfer, Katrein
AU - Sheik-Khalil, Enas
AU - Sköld, Annette
AU - Uchtenhagen, Hannes
AU - Vabret, Nicolas
AU - Ziglio, Serena
AU - Scarlatti, Gabriella
AU - Shattock, Robin
AU - Wahren, Britta
AU - Gotch, Frances
N1 - Funding Information:
More than 34 projects within the network are funded by the European Commission along with seven funded by the Gates Foundation and the NIH. Until now around 200 multi-author papers have been published in high impact journals, a weekly news bulletin and science update is provided and is available to non-EUROPRISE colleagues worldwide. The network is a major hub for providing AIDS reagents. The network is fully described at http://www.europrise.org.
PY - 2011/4/12
Y1 - 2011/4/12
N2 - Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa.
AB - Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa.
UR - https://www.scopus.com/pages/publications/79953869416
U2 - 10.1186/1479-5876-9-40
DO - 10.1186/1479-5876-9-40
M3 - Review article
C2 - 21486446
AN - SCOPUS:79953869416
SN - 1479-5876
VL - 9
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
M1 - 40
ER -